Revival Healthcare Capital led the financing, which also included inside investor participation.
The Lausanne, Switzerland-based company plans to use the funding to accelerate the U.S. commercial adoption of Dexter, its soft tissue surgical robot system. Other uses could include further product development initiatives.
Distalmotion designed Dexter to deliver robotic benefits to more hospitals, outpatient departments and ambulatory surgical centers (ASCs). The modular, small-format, open system delivers simplicity and straightforwardness, plus more accessibility, Distalmotion says.
According to the company, Dexter can work natively with third-party 3D imaging systems, energy devices, vessel sealers and other laparoscopic devices. It features a suite of fully wristed, single-use instruments. These instruments offer dexterity, precision of movement, reliable instrument performance and lower reprocessing requirements.
For more on the wide world of surgical robotics and companies like Distalmotion, see our special report on the space.
Dexter recently received FDA clearance for total benign hysterectomy as well as oophorectomy, salpingectomy, and other gynecologic procedures. It marks the third approved indication in the U.S. after FDA nods for inguinal hernia repair and cholecystectomy.
Distalmotion said it continues to put significant focus toward expansion in the ASC market. The fast-growing surgical care segment signals a shift toward efficient, outpatient surgery, potentially made easier with Dexter.
“This funding marks another important milestone on our journey,” said Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for Dexter. The ongoing support from our investors reaffirms our roadmap, our mission, and the value Dexter brings to minimally invasive surgery.”
Distalmotion adds industry veteran as board chair
In conjunction with the financing, Distalmotion named Chas McKhann the executive chair of its board. McKhann brings more than 25 years of experience in the medtech and life sciences industries.
His track record includes scaling medical device companies, commercial acceleration and guiding organizations through strategic growth. He previously served as CEO of Apollo Endosurgery, then Silk Road Medical, leading them both through successful exits through acquisitions by Boston Scientific.
Distlamotion said the appointment of McKhann underscores its commitment to establish a Dexter leadership position in ASCs.
“I am thrilled to join the Distalmotion team,” said McKhann. “Distalmotion has reimagined how robotic surgery can be adopted across care settings because Dexter delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value. With the recent FDA clearance in gynecology and release of Dexter product enhancements, the company is poised to accelerate adoption in the US and globally at this pivotal stage in its growth trajectory.”
